# Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling for Iron-Regulated Hematopoietic Stem and Progenitor Cells’ Commitment toward Erythroid and Megakaryocytic Lineages

## TL;DR

This study shows how iron affects blood cell development, particularly red blood cells and platelets, and introduces a model to better understand and optimize iron therapy for anemia.

## Contribution

A mechanism-based pharmacokinetic/pharmacodynamic model was developed to quantify iron's impact on erythroid and megakaryocytic lineage commitment.

## Key findings

- Iron increases erythroid cells while reducing megakaryocytic cells in hematopoietic stem and progenitor cells.
- The MAPK/ERK pathway mediates iron-regulated lineage commitment in HSPCs.
- Iron supplementation reverses anemia effects in rats and works synergistically with erythropoietin.

## Abstract

Iron replenishment is a cornerstone therapy for anemia
in diverse
diseases. While its role in erythrocyte hemoglobinization is well-established,
the broader impact of iron on other aspects of hematopoiesis, such
as thrombopoiesis, remains poorly understood. In this study, we demonstrate
that iron plays a regulatory role in the commitment of hematopoietic
stem and progenitor cells (HSPCs) toward erythroid and megakaryocytic
lineages. Using colony-forming unit assays and flow cytometry, we
observed that iron increases the proportion of erythroid cells while
reducing the proportion of megakaryocytic cells. Transcriptomic profiling
and functional output analyses identified the MAPK/ERK pathway as
a critical mediator of iron-regulated HSPCs’ commitment. Corroborating in vitro findings, rats with iron deficiency anemia exhibited
continuously elevated platelets and decreased red blood cell counts,
while intravenous iron supplementation reversed these effects. This
effect of iron was enhanced in combination with erythropoietin, a
key cytokine in erythropoiesis. A mechanism-based pharmacokinetic/pharmacodynamic
model was developed to quantify the impact of iron on the two lineages.
The dynamic interplay between iron levels and the development of erythropoiesis
and thrombopoiesis was accurately recapitulated in rats. The model
was further extrapolated to humans and validated with clinical data.
Overall, this work not only provides functional insights into the
pivotal role of iron in erythropoiesis and thrombopoiesis but also
holds translational implications for optimizing iron therapy in anemia
and potentially other hematologic conditions where erythropoiesis
and thrombopoiesis are affected.